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Abstract
Background: The results of prostate specific antigen (PSA) and digital rectal examination (DRE) screenings lead to both
under and over treatment of prostate cancer (PCa). As such, there is an urgent need for the identification and evaluation of
new markers for early diagnosis and disease prognosis. Studies have shown a link between PCa, lipids and lipid metabolism.
Therefore, the aim of this study was to examine the concentrations and distribution of serum lipids in patients with PCa as
compared with serum from controls.
Method: Using Electrospray ionization mass spectrometry (ESI-MS/MS) lipid profiling, we analyzed serum phospholipids
from age-matched subjects who were either newly diagnosed with PCa or healthy (normal).
Results: We found that cholester (CE), dihydrosphingomyelin (DSM), phosphatidylcholine (PC), egg phosphatidylcholine
(ePC) and egg phoshphatidylethanolamine (ePE) are the 5 major lipid groups that varied between normal and cancer
serums. ePC 38:5, PC 40:3, and PC 42:4 represent the lipids species most prevalent in PCa as compared with normal serum.
Further analysis revealed that serum ePC 38:5 $0.015 nmoles, PC 40.3 #0.001 nmoles and PC 42:4 #0.0001 nmoles
correlated with the absence of PCa at 94% prediction. Conversely, serum ePC 38:5 #0.015 nmoles, PC 40:3 $0.001 nmoles,
and PC 42:4 $0.0001 nmoles correlated with the presence of PCa.
Conclusion: In summary, we have demonstrated that ePC 38:5, PC 40:3, and PC 42:4 may serve as early predictive serum
markers for the presence of PCa.
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Introduction
Prostate cancer (PCa) is the most commonly diagnosed cancer
in men and the second leading cause of cancer deaths in men in
the western world [1,2]. However, incidence rates of PCa differ
throughout the world, suggesting that external factors, for example
a high-fat diet, may contribute to disease development [3]. While
PCa already poses a significant threat to the health of the U.S.
population, the aging of the ‘‘baby boomer’’ generation will
significantly exacerbate this problem [4]. The age specific
incidence of PCa increases after age 60, and in 2 years, 80
million ‘‘baby boomers’’ will approach this milestone.
Screening for prostate cancer is controversial in light of the fact
that the two major screening methods for PCa, the digital rectal
examination (DRE) and the serum prostate-specific antigen (PSA)
test, have limitations [5]. PSA, in combination with morphology-
based factors such as clinical stage and biopsy Gleason sum, is used
most commonly to diagnose and monitor prostate disease
progression, but has limited efficacy due to less than ideal
specificity and sensitivity. Several other PCa diagnostic and
prognostic markers have been discovered and are currently being
evaluated as potential adjuncts to existing screening techniques
[6]. However, there remains an urgent need for the identification
and evaluation of new markers to assist in early diagnosis and
disease prognosis to guide clinicians in providing treatment
appropriately.
Lipids play an important role in biological functions, including
membrane composition and regulation, energy metabolism, and
signal transduction [7], and so not surprisingly, they have been
found to be involved in cancer [8]. In particular, lipids, such as
phosphatidylcholine (PC) and fatty acids, play a key role PCa
development and metastasis [9,10]. Indeed, studies show an
association between high dietary fat consumption and a greater
risk for PCa [11,12] as well as the potential of serum
phospholipids levels to serve as predictors for PCa [13]. Since
many studies have demonstrated that lipids play a critical role
in PCa, the objective of our study was to investigate whether
or not serum lipid profiling could discriminate between those
with PCa and normal individuals, and subsequently the
potential of these lipids to act as diagnostic markers for PCa
screening.
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Materials and Methods
Human serum samples from controls and individuals
with PCa
This study was approved (expedited) by Memorial University
Medical Center (MUMC) human subjects and ethics committee.
ProMedDX, Massachusetts provided all serum samples (http://
www.promeddx.com). Coded specimens were sent in a frozen
state, and the laboratory personnel were blinded as to which of the
specimens was from patients or normal individuals until after all of
the clinical data and laboratory results became available. Initially,
we analyzed the lipid profiles of 154 total serum samples: 77 from
prostate cancer patients and 77 from normal subjects. For further
statistical analysis, we divided serum samples into two groups:
Samples from individuals 50–60 years in age and 61–70 years in
age. As we were conducting an age-matched study, we excluded
samples from those outside of the two age groups, which resulted
in 76 normal (one sample data had an error) and 57 PCa samples.
The study has been approved by the institutional review board.
For detail medical history of PCa patient please refer to Data S1.
Lipid extraction
Lipids from PCa and normal sera were extracted with
chloroform and methanol, following the protocol established by
the Kansas Lipidomics Research Center (KLRC); the method is
an adaptation of the method described by Bligh and Dyer [14].
Data processing
Data was processed using mass-spectrometer-specific software in
conjunction with Excel.
Electrospray ionization mass spectrometry (ESI-MS/MS)
lipid profiling
An automated electrospray ionization-tandem mass spectrom-
etry approach was used, and data acquisition and analysis were
carried out as described previously [15,16] with modifications. An
aliquot of 3 ml of plasma was used. Precise amounts of internal
standards, obtained and quantified as previously described [17],
were added in the following quantities (with some small variation
in amounts in different batches of internal standards): 0.60 nmol
di12:0-PC, 0.60 nmol di24:1-PC, 0.60 nmol 13:0-lysoPC,
0.60 nmol 19:0-lysoPC, 0.30 nmol di12:0-PE, 0.30 nmol di23:0-
PE, 0.30 nmol 14:0-lysoPE, 0.30 nmol 18:0-lysoPE, 0.30 nmol
14:0-lysoPG, 0.30 nmol 18:0-lysoPG, 0.30 nmol di14:0-PA,
0.30 nmol di20:0 (phytanoyl)-PA, 0.20 nmol di14:0-PS, 0.20 nmol
di20:0(phytanoyl)-PS, 0.23 nmol 16:0-18:0-PI, 0.16 nmol di18:0-
PI, 2.5 nmol C13:0 CE, and 2.5 nmol C23:0 CE. The sample and
internal standard mixture was combined with solvents, such that
the ratio of chloroform/methanol/300 mM ammonium acetate in
water was 300/665/35, and the final volume was 1.2 ml. This
mixture was centrifuged for 15 min at low speed to pellet
particulates before presenting to the autosampler.
Unfractionated lipid extracts were introduced by continuous
infusion into the ESI source on a triple quadrupole MS (API 4000,
Applied Biosystems, Foster City, CA). Samples were introduced
using an autosampler (LC Mini PAL, CTC Analytics AG,
Zwingen, Switzerland) fitted with the required injection loop for
the acquisition time and presented to the ESI needle at 30 ml/min.
Sequential precursor and neutral loss scans of the extracts
produce a series of spectra with each spectrum revealing a set of
lipid species containing a common head group fragment. Lipid
species were detected with the following scans: PC, SM, and
lysoPC, [M+H]+ ions in positive ion mode with Precursor of 184.1
(Pre 184.1); PE and lysoPE, [M+H]+ ions in positive ion mode
with Neutral Loss of 141.0 (NL 141.0); PI, [M+NH4]+ in positive
ion mode with NL 277.0; PS, [M+NH4]+ in positive ion mode
with NL 185.0; PA, [M+NH4]+ in positive ion mode with NL
115.0; CE, [M+NH4]+ in positive ion mode with Pre 369.3. SM
was determined from the same mass spectrum as PC (Pre 184.1 in
positive mode) [18,19] and by comparison with PC internal
standards using a molar response factor for SM (in comparison
with PC) determined experimentally to be 0.39.The collision gas
pressure was set at 2 (arbitrary units). The collision energies, with
nitrogen in the collision cell, were +28 V for PE, +40 V for PC
(and SM), +25 V for PI, PS and PA, and +30 V for CE.
Declustering potentials were +100 V for all lipids except CE, for
which the declustering potential was +225 V. Entrance potentials
were +15 V for PE, +14 V for PC (and SM), PI, PA, and PS, and
+10 V for CE. Exit potentials were +11 V for PE, +14 V for PC
(and SM), PI, PA, PS, and +10 V for CE. The mass analyzers were
adjusted to a resolution of 0.7 u full width at half height. For each
spectrum, 9 to 150 continuum scans were averaged in multiple
channel analyzer (MCA) mode. The source temperature (heated
nebulizer) was 100uC, the interface heater was on, +5.5 kV or
24.5 kV were applied to the electrospray capillary, the curtain gas
was set at 20 (arbitrary units), and the two ion source gases were
set at 45 (arbitrary units).
Table 1. Flow chart of statistical strategy for identification of
novel phospholipid.
No of age matched samples: 133 (Cases: 57, Controls: 76)
Y
Mass Spectrometry for lipid analysis (Total No. of lipids: 354)
Y
False discovery rate (FDR) (P-value,0.05) to control the false discoveries in
multiple hypothesis testing
Y
31 lipids were selected through FDR and used for further analysis
Y
Odds ratio and relative risk
Y
Final 3 lipids were selected for further analysis (ePC 38:5, PC 40:3 and PC 42:4)
Y
Cut points decided (0.015nmole for ePC 38:5, 0.001nmole for PC40:3,
0.0001nmole for PC 42:4)
Y
Logistic regression of Panel of three lipids (ePC 38:5, PC 40:3 and PC 42:4 for the
Note: Receiver Operating Characteristic Curve for accuracy of panel (Panel-
0.9157; ePC38:5- 0.7149; PC40:3- 0.8268; PC42:4-0.8509).
doi:10.1371/journal.pone.0088841.t001
Table 2. Distribution of samples.
Age (Years)
Normal Control
(n = 76)
Prostate Cancer Cases
(n=57)
50–60 30 24
61–70 46 33
doi:10.1371/journal.pone.0088841.t002
Phospholipids Stratify Normal and Prostate Cancer
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Table 3. Age-matched prostate cancer subjects were identified with their PSA and Gleason scores (medical history) gives a
baseline of study cases and controls.
Prostate Cancer Subjects Normal Subjects
ProMedDx Age PSA Gleason Matrix Gender ProMedDx Age
number Score number
11505131 44 na 7 Serum M 11585237 50
11000244 50 3.55 7 Serum M 11585245 50
11505133 50 na 6 Serum M 11585299 51
11505138 53 na 7 Serum M 11607890 52
11557623 56 na 7 Serum M 11584113 53
11505129 55 na 7 Serum M 11584148 53
11625321 51 na 7 Serum M 11607800 53
11518554 52 na 6 Serum M 11607813 53
11518558 53 na 6 Serum M 11607832 53
11505132 53 na 6 Serum M 11584185 54
11381070 55 na 9 Serum M 11584945 54
11505134 56 na 6 Serum M 11584976 55
11505135 56 na 6 Serum M 11585046 55
11505136 56 na 6 Serum M 11584245 56
11381068 57 na 7 Serum M 11584286 56
11518535 57 6.8 9 Serum M 11585303 56
11518538 57 1 6 Serum M 11584288 57
11518550 57 na 7 Serum M 11585153 57
11557622 57 4.9 7 Serum M 11585314 57
11505139 58 na 8 Serum M 11585319 57
11625323 58 na 7 Serum M 11585351 57
11382587 59 0.1 7 Serum M 11584933 58
11625325 59 na 6 Serum M 11585739 58
11382594 60 na 7 Serum M 11586140 58
11518559 60 na 6 Serum M 11585132 59
11246504 65 na 7 Serum M 11585521 59
11246505 65 ,0.1 6 Serum M 11609074 59
11246506 65 na 6 Serum M 11584151 60
11505141 67 na 6 Serum M 11585550 60
11505140 70 na 8 Serum M 11608571 60
11518557 69 na 7 Serum M 11584882 61
11381073 61 na 6 Serum M 11585362 61
11382586 61 6 7 Serum M 11583437 62
11518540 61 na 6 Serum M 11584835 62
11518551 61 na 7 Serum M 11585147 62
11246508 62 na 7 Serum M 11585306 62
11381058 62 na 6 Serum M 11585473 62
11518537 62 na 6 Serum M 11585705 62
11518544 62 6.4 6 Serum M 11585754 62
11382590 63 ,0.1 7 Serum M 11586037 62
11518542 63 na 7 Serum M 11600540 62
11381062 64 na 6 Serum M 11607895 62
11625315 64 na 7 Serum M 11608013 62
11505143 65 na 6 Serum M 11608056 62
11518546 65 na 7 Serum M 11608390 62
11381072 66 na 6 Serum M 11608457 62
Phospholipids Stratify Normal and Prostate Cancer
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The background of each spectrum was subtracted, the data
were smoothed, and peak areas integrated using a custom script
and Applied Biosystems Analyst software, and the data were
corrected for overlap of isotopic variants (A+2 peaks). The lipids in
each class were quantified in comparison to the two internal
standards of that class. The first and typically every 11th set of mass
spectra were acquired on the internal standard mixture only. Peaks
corresponding to the target lipids in these spectra were identified
and molar amounts calculated in comparison to the internal
standards on the same lipid class. To correct for chemical or
instrumental noise in the samples, the molar amount of each lipid
metabolite detected in the ‘‘internal standards only’’ spectra was
subtracted from the molar amount of each metabolite calculated in
each set of sample spectra. The data from each ‘‘internal standards
only’’ set of spectra was used to correct the data from the following
10 samples. Finally, the data were corrected for the fraction of the
sample analyzed and normalized to the sample ‘‘dry weights’’ to
produce data in the units nmol/mg. The result of this analysis
provided a total of 354 potential lipids for early identification of
the presence of PCa.
Statistical analyses
To identify potential models using the 354 lipids that were
identified, the analysis involved multiple iterations of ‘‘best
subsets’’ logistic regression. The analysis was performed as
frequently found in ‘‘high through-put’’ data analysis, as limiting
models to no more than 3 lipids is equivalent to a genomics
problem of over seven million potential biomarkers. Examples of
this type of analysis are well-documented [20–25]. Cross-
classifications and logistic regression models were employed to
screen the data for potential predictor candidates. A standard
approach to analysis in univariate hypothesis testing is to select an
appropriate test, fix the type I error rate at a pre-specified value,
decide on an appropriate level of power and determine the
Table 3. Cont.
Prostate Cancer Subjects Normal Subjects
ProMedDx Age PSA Gleason Matrix Gender ProMedDx Age
11518552 66 na 9 Serum M 11608786 62
11381069 67 na 9 Serum M 11608876 62
11518543 67 na 6 Serum M 11608993 62
11625319 67 3.8 7 Serum M 11584232 63
11381071 68 na 6 Serum M 11585732 63
11382595 68 0.8 9 Serum M 11585753 63
11382596 68 ,0.1 6 Serum M 11608287 63
11518545 68 2.9 6 Serum M 11608780 63
11246507 70 na 6 Serum M 11608846 63
11382581 70 na 7 Serum M 11608942 63
11518556 70 na 6 Serum M 11585756 64
11625322 70 3.7 7 Serum M 11585805 64
11625310 71 9.7 6 Serum M 11585855 64
11518553 73 na 8 Serum M 11585876 64
10935542 72 1.9 6 Serum M 11600563 64
11381063 71 3.6 6 Serum M 11608019 64
11381064 71 na 6 Serum M 11608251 64
11518536 71 na 6 Serum M 11608867 64
11518547 71 na 6 Serum M 11609027 64
11625324 71 na 7 Serum M 11566664 65
11518539 73 5 6 Serum M 11584922 65
11518548 73 na 7 Serum M 11585512 65
11518549 74 na 6 Serum M 11585629 65
11625314 74 na 7 Serum M 11585724 65
11381065 79 3.1 6 Serum M 11608994 65
11505142 80 na 6 Serum M 11608936 66
11505137 83 na 7 Serum M 11608078 67
11518555 81 na 7 Serum M 11586047 68
11142413 82 4.9 6 Serum M 11586062 68
11518541 84 na 7 Serum M 11585744 69
11625311 84 na 7 Serum M 11586054 69
The bolded segment of the ProMedDx numbers are the subjects that did not fall in our age-match category.
doi:10.1371/journal.pone.0088841.t003
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necessary sample size. As the analysis in this research mirrors that
found in genomics, we employed the false discovery rate to help in
the selection of lipids to use in the models. Statistically, the false
discovery rate is the expected value of the number of type I errors
divided by the number of rejected hypotheses, given at least one
hypothesis is rejected [24]. The false discovery rate (FDR) is a
common approach in simultaneous testing developed by Benja-
Table 4. False Discovery Rate (FDR) (P-value,0.05) to control the false discoveries in multiple hypothesis testing.
Lipid molecular Species Compound Formula Nominal Mass False Discovery Rate (FDR) (P,0.05)
C19:1CE C46H84NO2 682.7 ,.0001
C20:0CE C47H88NO2 698.7 ,.0001
C20:1CE C47H86NO2 696.7 ,.0001
C20:2CE C47H84NO2 694.7 0.0014
DSM 16:0 C39H81N2O6P 705.6 0.0063
LPE 16:0 C21H44O7PN 454.3 0.0037
PC 38:0 C46H92O8PN 818.7 0.0050
PC 40:2 C48H92O8PN 842.7 ,.0001
PC 40:3 C48H90O8PN 840.6 ,.0001
PC 40:7 C48H82O8PN 832.6 0.0011
PC 42:10 C50H80O8PN 854.6 0.0004
PC 42:2 C50H96O8PN 870.7 ,.0001
PC 42:3 C50H94O8PN 868.7 ,.0001
PC 42:4 C50H92O8PN 866.7 ,.0001
PC 42:5 C50H90O8PN 864.6 ,.0001
PC 42:8 C50H84O8PN 858.6 ,.0001
PC 42:9 C50H82O8PN 856.6 0.0002
ePC 36:1 C44H88O7PN 774.6 ,.0001
ePC 36:5 C44H80O7PN 766.6 0.0040
ePC 38:1 C46H92O7PN 802.7 ,.0001
ePC 38:2 C46H90O7PN 800.6 ,.0001
ePC 38:3 C46H88O7PN 798.6 ,.0001
ePC 38:5 C46H84O7PN 794.6 0.0007
ePC 38:6 C46H82O7PN 792.6 0.0053
ePC 40:2 C48H94O7PN 828.7 ,.0001
ePC 40:3 C48H92O7PN 826.7 ,.0001
ePC 40:4 C48H90O7PN 824.6 ,.0001
ePC 40:5 C48H88O7PN 822.6 ,.0001
ePE 34:1 C39H78O7PN 704.6 0.0001
ePE 36:3 C41H78O7PN 728.6 0.0072
ePE 38:0 C43H88O7PN 762.6 0.0022
doi:10.1371/journal.pone.0088841.t004
Table 5. Estimates of odds ratio for the three lipid species
ePC 38:5, PC 40:3 and PC 42:4, the reference group is the
Control Group.
ePC 38.5 PC40:3 PC42:4 % Prediction
Prediction of
Prostate
Cancer
#0.015 #0.001 #0.0001 61.84 Absent
#0.015 #0.001 $0.0001 9.46 Present
#0.015 $0.001 #0.0001 28.12 Present
#0.015 $0.001 $0.0001 2.46 Present
$0.015 #0.001 #0.0001 94.22 Absent
$0.015 #0.001 $0.0001 51.25 Absent
$0.015 $0.001 #0.0001 79.74 Absent
$0.015 $0.001 $0.0001 20.25 Present
doi:10.1371/journal.pone.0088841.t005
Table 6. Prediction of disease based on sensitivity analysis.
Odds Ratio Estimates
Lipid species
Odds Ratio (Cases/
Controls)
95% Confidence
Interval
ePC 38:5 10.061 2.938–34.447
PC 40:3 0.241 0.060–0.976
PC 42:4 0.064 0.015–0.272
doi:10.1371/journal.pone.0088841.t006
Phospholipids Stratify Normal and Prostate Cancer
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mini and Hochberg [26]. The FDR is commonly used in medicine
and genomic studies. Once a small subset of lipids was selected,
logistic regression models were constructed and compared using
the lipid values as continuous variables. The final model consisted
of three lipids. As the lipids were considered continuous, Receiver
Operating Characteristic (ROC) curves were employed to
determine optimal cut-points which allow for ease in use and
interpretation [27,28](G,H). The cut-points were determined by
maximizing the area under the curve, AUC. The resultant AUC
using the three lipids in the logistic regression derived composite
index is 0.9157. All statistical analyses were performed using SAS
9.2TM (SAS Institute, Inc., Cary, NC.).
Please see flow Table 1 for our statistical strategy for
identification of novel phospholipids.
Results
Egg phosphatidylcholine (ePC 38:5), Phosphatidylcholine
(PC 40:3 and PC 42:4) were identified as unique
candidate for disease diagnosis
To identify specific serum lipids species associated with PCa, we
performed MS analyses. Given the necessity of simultaneously
comparing hundreds of lipids, we incorporated the false discovery
rate (FDR) into our analyses [29,30]. Tables 2 and 3 provide
details of the aged-matched serum samples; including the Gleason
scores and PSA levels for patients diagnosed with PCa (the full
medical history can be found in Data S1). Samples highlighted in
gray were from individuals outside of our age range and were
therefore not included in the analyses. Data collected from the
Kansas Lipidomics Research Center (KLRC) and processed using
MS-specific software in conjunction with Excel revealed 354
different species of lipids (for details please refer Data S2). Using a
FDR value of P,0.05, we identified 31 lipids statistically
significantly associated with PCa (Table 4). These lipid species
are from five major groups: cholester (CE), dihydrosphingomyelin
(DSM), phosphatidylcholine (PC), egg phosphatidylcholine (ePC)
and egg phoshphatidylethanolamine (ePE).
We next determined that odds ratio and relative risk for the 31
lipid species identified by MS. Table 5 shows that the odds ratio
(with 95% confidence interval [CI]) of the three lipids, ePC 38:5,
PC 40:3 and PC 42:4 equals 10.061, 0.241 and 0.064, respectively.
We next performed a sensitivity analysis based on these values
(Table 6). For each of the individual lipids, we controlled for any
confounding effects of the remaining two. For example, with PC
40:3, the odds ratio is 0.241, which indicates that after controlling
the confounding effect of ePC 38:5 and PC 42:4, individuals whose
level of PC 40:3 is greater than 0.001 nmoles are less likely to be
‘‘normal-appearing’’ as compared with those whose level of PC
Figure 1. Receiver Operating Curve (ROC) for the panel of the three lipids ePC 38:5, PC40:3, and PC 42:4, for prediction of the
presence or absence of PCa. X axis: 1-specificity; Y axis: sensitivity. Area under curve = 0.9157. ROC1: ---------; ROC2: -.-.-.-.; ROC3: ______ ___, and
Model: _________.
doi:10.1371/journal.pone.0088841.g001
Table 7. Sensitivity analyses for the panel of three lipids ePC
38:5, PC 40:3 and PC 42:4 for the prediction of prostate cancer.
Disease prediction, n =133 (100%)
Normal (Positive) Cancer (Negative)
Normal 71 (53.58%) 5 (3.76%)
n= 76 (True positive, TP) (False positive, FP)
Cancer 11 (8.27%) 46 (34.59%)
n= 57 (False negative, FN) (True negative, TN)
Sensitivity= TP/(TP+FN) = 90.20% Specificity= TN/(FP+TN) = 86.59%
True positive: 71, false positive: 5, true negative: 46 and, false negative: 11; with
90.20% sensitivity and 86.59% specificity respectively.
doi:10.1371/journal.pone.0088841.t007
Phospholipids Stratify Normal and Prostate Cancer
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40:3 is lower than 0.001 nmoles. In summary, the overall analyses
strongly suggests that individuals with serum levels of ePC 38:5
$0.015 nmoles are more likely to be cancer-free or normal
appearing, and individuals with serum levels of PC 42:4 $than
0.0001 nmoles are less likely to be normal as compared with those
with PC 40:3 levels #0.001 nmoles.
Disease prediction and validity of diagnostic test
We next evaluated whether ePC 38:5, PC 40:3, and PC42:4
could be used as a diagnostic test for PCa based on a sensitivity
analysis (Table 7). Using logistic regression with a sensitivity of
90.20% and a specificity of 86.59%, we would predict 71
individuals as true positive, 46 as true negative, 5 as false positive,
and 11 as false negative. In figure 1, we plotted a Receiver
Operating Characteristic (ROC) curve to examine the true
positive rate (Sensitivity) versus false positive rate (1-Specificity)
[31], as a measure of the inherent validity of our diagnostic test.
When we examined the three lipids individually for predicting
PCa, the accuracy of using ePC 38:5 alone was 0.7149 (ROC1),
for PC 40:3 was 0.8268 (ROC2), and for PC 42:4 was 0.8509
(ROC3). Looking at combinations of lipids, the ROC for PC40:3
and PC42:4 was 0.8822, for ePC 38:5 and PC42:4 was 0.9093 and
for ePC 38:5 and PC40:3 was 0.8852 (data not shown). However,
interestingly, using a combination of the three phospholipids (ePC
38:5, PC 40:3 and PC 42:4), resulted in an area of the curve (AUC)
of 0.9157. Thus, the three lipids can be used for discriminating
cancer versus normal status with an accuracy of ,92% based on
cut-off values (for their presence or absence) of 0.015 nmole for
ePC 38:5, 0.001 nmole for PC 40:3, and 0.0001 nmole for PC 42:4
[8]. We thus conclude that if ePC 38:5 is present in serum sample
$0.015 nmole and if PC 40.3 #0.001 nmole and PC 42:4
#0.0001 nmole; then we predict (95% confidence) that PCa is
absent and the individual is normal. Conversely, if ePC 38:5
#0.015 and both PC 40:3 and PC 42:4 are greater than 0.001 and
0.0001 respectively; then the presence of PCa is very likely.
Discussion
Currently, the major problem in PSA testing is either over-
and/or under- diagnosis. On one hand, nearly 15–25% of men
have PCa even though their PSA levels are normal (4.0 ng/mL or
less) [32,33].On the other hand, high PSA levels are observed in
men with benign prostate enlargement (BPH), prostatitis or
indolent cancers [34], and data suggests that an estimated 40%
to 50% of cases undergo unnecessary overtreatment. Unfortu-
nately, urologists cannot embark on any specific therapeutic
options unless PCa is positively identified in a biopsy, and this
requires an additional 12–18 core biopsies, at a considerable cost
and morbidity [35].
The report on the Prostate, Lung, Colorectal, and Ovarian
(PLCO) Cancer Screening trial notes that screening was not
associated with a reduction in PCa mortality during the first 7
years of the trial (rate ratio, 1.13). These results support the validity
of the recent U.S. Preventive Services Task Force recommenda-
tions against screening all men over the age of 75 years [33].
Furthermore, there is no evidence that the balance of benefits and
harms from PSA screening differs for African Americans and
whites [36,37]. Therefore, a major strength of this study is that the
levels of ePC 38:5, PC 40:3, PC 42:4 can be used to accurately
predict the presence of PCa, with a . high sensitivity of 90.20%
and specificity of 86.59%. Moreover, we used age-matched
samples from individuals ranging in age from 50 to 70 year; thus,
this panel of lipids could differentiate between the presence and
absence of PCa in individuals who were relative young. It is
conceivable that if phospholipid profile is used in conjunction with
PSA and DRE screening tests, there is a high likelihood of
detecting PCa early-on. By using this panel as a screening test, we
hope to help patients make informed decisions about whether or
not to opt for surgery or other treatments that may not be
necessary and that may negatively affect their quality of life.
Studies suggest that certain genetic events that can lead to
malignant progression may only occur in cancer precursors
(‘‘genetic events indicative of precursor PIN’’), and not in non-
precursor prostatic intraepithelial neoplasia (PINs). Our previous
study [38] suggests that we can distinguish the cancer precursor
PINs from the benign PINs by a specific change in the 15-
lipoxygenase-1 (15-LO-1) promoter DNA methylation status.
Similarly, abnormalities in phospholipid metabolism can also
represent hallmarks of cancer cells, especially since alterations in
phospholipids are associated with malignant transformation,
tumorigenicity and metastasis. Therefore, fatty acids and lipid
composition can also potentially be markers of carcinogenesis
[39,40]. Previously, there has been an effort to identify candidate
lipid biomarkers of PCa by shotgun lipidomics. Qualitative and
quantitative profiling of six different categories of urinary
phospholipids from patients with PCa were performed, but the
results were inconclusive [41]. Thus, urinary metabolites may not
be reliable biomarkers for PCa detection or for differentiating
between indolent and aggressive tumors. Our study, however
using serum shows specific differences in the phospholipid profile
between individuals who lack tumors (normal) and those who have
PCa.
Multiple studies have shown an association between PCa risk
and diet. For example, Norrish and colleagues demonstrated that
dietary fish oils may lower PCa risk, possibly through inhibition of
Arachidonic acid-derived eicosanoid biosynthesis [42]. Similarly, a
positive association exists between Palmitic acid and an overall risk
of PCa while there is an inverse association between PCa and
stearic acid [43], as well as with phosphatidylcholine [41].
Choline, an essential micronutrient necessary for cell membrane
synthesis and phospholipid metabolism, also functions as an
important methyl donor. Choline can modify DNA and impact
cell signaling via intermediary phospholipid metabolites, influenc-
ing cell proliferation [36].
For detecting several of the fatty acids, measuring the fatty acid
composition of serum phospholipids may give a better reflection of
actual consumption of dietary fat than dietary assessment
techniques. In fact, fatty acids in serum reflect dietary fat intake
in the post-absorptive phase, so processes that affect the
bioavailability of fatty acids, such as their transport, excretion,
and metabolism, are taken into account [43]. Lipidomics
potentially provides detailed information on a wide range of
individual serum lipid metabolites. Using this approach, our study
has identified potentially interesting species of cholester (CE),
dihydrosphingomyelin (DSM), phosphatidylcholine (PC), egg
phosphatidylcholine (ePC) and egg phoshphatidylethanolamine
(ePE) that are associated with PCa. While fatty acids in adipose
tissue seem to better reflect habitual dietary fat intake of some fatty
acids than in blood [44], adipose tissue aspirates are more difficult
to collect than blood samples in large-scale prospective studies.
Moreover, adipose tissue is predominantly made up of triacylgly-
cerol and may not be the lipid of choice for measuring fatty acids
because of a smaller proportion of these fatty acids being
incorporated into this lipid fraction [45].
In conclusion, because of consistency and robustness, specific
phospholipids identified in our study fit the criteria for a phase 1/2
markers [46], especially if they can be combined with PSA and
DRE screening for the diagnosis of PCa. Our data suggests that if
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the ePC 38:5 present in the serum sample is greater than 0.015
nmoles, the PC 40:3 is less than 0.001 nmoles and the PC 42:4 is
less than 0.0001 nmoles, then the predictability of the absence of
PCa is 94%. Conversely, if the ePC 38:5 is less than 0.015 nmoles,
the PC 40:3 is greater than 0.001 nmoles, and the PC 42:4 is
greater than 0.0001 nmoles, then the predictability of the presence
of PCa is very high. Therefore, a combination of serum ePC 38:5,
PC 40:3 and PC 42:4 can be used as a surrogate for the presence
PCa. With the information gained from our study, we will
continue using the lipidomics strategy in a larger data-set of
normal and PCa patient serum samples to validate our findings.
Limitations of this study are that the number of available samples
did not allow us to divide the samples into a training sample and
validation sample, there was no PSA values in the patient cohort
and also no information on whether or not it was a representative
patient cohort.. As a result, we recognize that our model most
likely overestimates the true sensitivity and true specificity. As
replication is the cornerstone of all scientific research it is our hope
that this work is validated with additional investigations.
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